Get the Stockscreener App
27.50
2.23%
0.60
Spyre Therapeutics Inc stock is traded at $27.50, with a volume of 1.24M.
It is up +2.23% in the last 24 hours and down -16.06% over the past month.
See More
Previous Close:
$26.90
Open:
$26.86
24h Volume:
1.24M
Relative Volume:
2.27
Market Cap:
$1.58B
Revenue:
$1.23M
Net Income/Loss:
$-185.98M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-156.42M
1W Performance:
-16.62%
1M Performance:
-16.06%
6M Performance:
-25.41%
1Y Performance:
+0.00%
1-Day Range:
$26.81
$28.48
1-Week Range:
$25.74
$33.47
52-Week Range:
$10.42
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SYRE | 27.50 | 1.58B | 1.23M | -185.98M | -156.42M | 0.00 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire
Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat
Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN
Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire
Spyre Therapeutics revises net loss per share calculations - Investing.com
Spyre Therapeutics launches $200 million public offering - Investing.com
Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan
Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat
Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com
SYRE Crosses Below Key Moving Average Level - Nasdaq
Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com
Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com
Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat
Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia
FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com
Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World
Spyre reports promising Phase 1 results for IBD therapy - Investing.com India
Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World
Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan
Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat
Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK
Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com
Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World
Spyre Therapeutics director sells shares worth $10,929 - Investing.com
Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa
Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat
Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SPY-003, an extended half-life MAb with twice-a-year projected human maintenance dosing - BioWorld Online
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News
Wedbush’s latest rating for SYRE stock - Knox Daily
SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat
Spyre Therapeutics Advances SPY003 for IBD Treatment - TipRanks
Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):